Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study

Oruc, Zeynep; Kaplan, Muhammet; Geredeli, Caglayan; Sari, Nilgun; ÖZASLAN, Ersin; Aytekin, Aydin; ELKIRAN, EMİN; Koca, Sinan; Dogan, Mutlu; TURAN, NEDİM; Yuce, Ozlem; Sevinc, Alper; Ercelep, Ozlem; Isikdogan, Abdurrahman

Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study

Atıf İçin Kopyala

Oruc Z., Kaplan M. A., Geredeli C., Sari N. Y., ÖZASLAN E., Aytekin A., ...Daha Fazla

JOURNAL OF BUON, cilt.25, sa.2, ss.641-647, 2020 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 25 Sayı: 2
Basım Tarihi: 2020
Dergi Adı: JOURNAL OF BUON
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
Sayfa Sayıları: ss.641-647
Erciyes Üniversitesi Adresli: Hayır

Özet

Purpose: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients.